2021
DOI: 10.2147/jir.s332943
|View full text |Cite
|
Sign up to set email alerts
|

Bacterial Lipopolysaccharide Augmented Malignant Transformation and Promoted the Stemness in Prostate Cancer Epithelial Cells

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

0
3
0

Year Published

2022
2022
2023
2023

Publication Types

Select...
5

Relationship

1
4

Authors

Journals

citations
Cited by 6 publications
(4 citation statements)
references
References 61 publications
0
3
0
Order By: Relevance
“…Many studies have shown that lipopolysaccharide (LPS) is involved in the proliferation, invasion, and metastasis of prostate cancer cells [27][28][29]. Recently, it has been found that intracellular LPS can activate the Caspase-4/5/11 pathway, induce pyroptosis, and inhibit tumour growth.…”
Section: Pyroptosis In Prostate Cancermentioning
confidence: 99%
“…Many studies have shown that lipopolysaccharide (LPS) is involved in the proliferation, invasion, and metastasis of prostate cancer cells [27][28][29]. Recently, it has been found that intracellular LPS can activate the Caspase-4/5/11 pathway, induce pyroptosis, and inhibit tumour growth.…”
Section: Pyroptosis In Prostate Cancermentioning
confidence: 99%
“…In addition to IL6/gp130, STAT3 activation can be fulfilled by other factors. The literature reveals that monoamine oxidative A (MAOA), HOX transcript antisense RNA (HOTAIR), interleukin 10 (IL-10) and bacterial lipopolysaccharide (LPS) enable an increase in PCSC population via driving STAT3 signaling [96][97][98].…”
Section: Janus Kinase-signal Transducer and Activator Of Transcriptio...mentioning
confidence: 99%
“…These conflicting reports appear consistent when organized by model type and route of administration. For example, pro-tumor effects of LPS are consistently reported in (immunedeficient) animal models, or isolated cancer cells in vitro (without an immune coculture) or by assumptions drawn on greater expression levels for TLR4 reported in cancer vs. healthy adjacent tissue (164)(165)(166)(167)(168)(169)(170)(171)(172)(173)(174)(175). However, anti-tumor effects of LPS/TLR4 agonists are consistently reported in fully immune competent animals, the majority showing greater survival time, curative remission in a significant % of test groups similar to Coley's toxin, reduction of adverse effects of chemotherapy and radiation, including resistance (130-133, 176-178), and effects augmented when combined with anti-tumor cytokines (e.g.…”
Section: Lps/trl4 Agonists and Cancer Modelsmentioning
confidence: 99%